Prevalence of M184V and K65R in proviral DNA from PBMCs in HIV-infected youths with lamivudine/emtricitabine exposure.

Santiago Jiménez de OryCarolina Beltrán-PavezMiguel Gutiérrez-LópezMaría Del Mar SantosLuis PrietoTalía SainzSara GuillenDavid Aguilera-AlonsoCristina DíezJose Ignacio BernardinoMaría José MelladoJosé Tomás RamosÁfrica HolguínMarisa Navarronull null

Published in: The Journal of antimicrobial chemotherapy (2021)

The prevalence of resistance mutations to lamivudine and emtricitabine in pDNA in a cohort of youths perinatally infected with HIV who remain with undetectable VL, previously lamivudine and/or emtricitabine experienced, was infrequent. Our results indicate that ART including lamivudine or emtricitabine may also be safe and successful in youths with perinatal HIV with previous experience of and resistances to these drugs detected in plasma.

Keyphrases

antiretroviral therapy
hiv infected patients
hiv infected
hiv positive
human immunodeficiency virus
hiv aids
risk factors
pregnant women
circulating tumor
cell free
south africa
hiv testing